Brokerages Set ICON Public Limited (NASDAQ:ICLR) Target Price at $287.00

Shares of ICON Public Limited (NASDAQ:ICLR - Get Free Report) have earned a consensus rating of "Moderate Buy" from the fifteen research firms that are presently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $287.00.

Several research analysts have recently issued reports on the stock. Barclays lowered their target price on shares of ICON Public from $330.00 to $275.00 and set an "overweight" rating for the company in a report on Friday, October 25th. Evercore ISI dropped their price objective on ICON Public from $360.00 to $350.00 and set an "outperform" rating on the stock in a report on Tuesday, October 8th. JPMorgan Chase & Co. reduced their target price on ICON Public from $375.00 to $280.00 and set an "overweight" rating for the company in a report on Friday, October 25th. Citigroup dropped their price target on ICON Public from $300.00 to $290.00 and set a "buy" rating on the stock in a research note on Monday, January 6th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $263.00 price objective on shares of ICON Public in a research note on Wednesday, January 15th.

Institutional Investors Weigh In On ICON Public

Several institutional investors and hedge funds have recently made changes to their positions in ICLR. Park Place Capital Corp lifted its position in shares of ICON Public by 281.4% in the fourth quarter. Park Place Capital Corp now owns 225 shares of the medical research company's stock valued at $47,000 after acquiring an additional 166 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of ICON Public by 64.0% during the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company's stock worth $91,000 after purchasing an additional 169 shares during the last quarter. Whittier Trust Co. of Nevada Inc. lifted its stake in shares of ICON Public by 23.1% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company's stock valued at $147,000 after buying an additional 96 shares during the period. First Horizon Advisors Inc. boosted its position in ICON Public by 33.9% during the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company's stock worth $172,000 after acquiring an additional 151 shares during the last quarter. Finally, Avior Wealth Management LLC raised its holdings in ICON Public by 76.0% in the 4th quarter. Avior Wealth Management LLC now owns 894 shares of the medical research company's stock valued at $187,000 after acquiring an additional 386 shares during the last quarter. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

ICON Public Stock Up 0.9 %

ICLR stock traded up $1.78 during trading on Monday, hitting $202.26. 848,498 shares of the company's stock were exchanged, compared to its average volume of 1,014,181. The stock has a market capitalization of $16.69 billion, a price-to-earnings ratio of 22.55, a PEG ratio of 1.52 and a beta of 1.20. ICON Public has a 52-week low of $183.38 and a 52-week high of $347.72. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. The business has a 50-day moving average price of $209.54 and a two-hundred day moving average price of $263.28.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.